Lucius LUCIAVAT Avatrombopag 20mg

Product Information

• Product name: LUCIAVAT Avatrombopag 20mg
• Manufacturer / brand: Laos Lucius Pharma
• Active ingredient: Avatrombopag
• Current strength: 20mg
• SKU: LU-ITEM-25
• Site category: platelet disorders

Product Summary

LUCIAVAT Avatrombopag 20mg is an AISTIKA-listed product supplied by Laos Lucius Pharma. This page summarizes the product identity, strength, SKU, site category, and public medical reference information. Product name, manufacturer, packaging, and strength follow this AISTIKA product page.

Active Ingredient and Reference Data

Avatrombopag is the active ingredient used for this product page. Public prescribing information for Avatrombopag was used for the medical reference sections. Medical details are provided for reference and must be interpreted by a qualified healthcare professional.

Mechanism of Action

Avatrombopag is an orally bioavailable, small molecule TPO receptor agonist that stimulates proliferation and differentiation of megakaryocytes from bone marrow progenitor cells, resulting in an increased production of platelets. Avatrombopag does not compete with TPO for binding to the TPO receptor and has an additive effect with TPO on platelet production.

Reference Indications

Avatrombopag is a thrombopoietin receptor agonist indicated for the treatment of: Thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. Thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. Thrombocytopenia in pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia who have had an insufficient response to a previous treatment 1.1 Treatment of Thrombocytopenia in Patients with Chronic Liver Disease (CLD) Avatrombopag is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.

Reference Dosage and Administration

Recommended Dose Adjustments for Adult Patients with Chronic Immune Thrombocytopenia and Pediatric Patients 6 Years and Older with Persistent or Chronic Immune Thrombocytopenia Platelet Count Dose Adjustment or Action Less than 50×10 9 /L after at least 2 weeks of Avatrombopag tablets Increase One Dose Level per Table 3. Administer immediately after mixing.

Dose conversion must be confirmed by a physician because the reference dose may vary by indication, organ function, toxicity, or interacting medicines.

This reference dosage is not an individualized prescription. Dose changes, treatment interruptions, or discontinuation must be directed by a physician.

Important Safety Information

Thrombotic/Thromboembolic Complications: Avatrombopag is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic liver disease or immune thrombocytopenia. Monitor for signs and symptoms of thromboembolic events and institute treatment promptly. Consider the potential increased thrombotic risk when administering Avatrombopag to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions (e.g., Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency or Protein C or S deficiency) and acquired risk factors (e.g., antiphospholipid syndrome). Avatrombopag should not be administered to patients with chronic liver disease or immune thrombocytopenia in an attempt to normalize platelet counts.

Common Adverse Reactions and Monitoring

Patients were divided into two groups based on their mean platelet count at baseline: Low Baseline Platelet Count Cohort (less than 40×10 9 /L) who received Avatrombopag 60 mg once daily for 5 days High Baseline Platelet Count Cohort (40 to less than 50×10 9 /L) who received Avatrombopag 40 mg once daily for 5 days The majority of patients were males (65%) and median subject age was 58 years (ranging from 19-86 years of age). The racial and ethnic distribution was White (60%), Asian (33%), Black (3%) and Other (3%). The most common serious adverse reaction reported with Avatrombopag was hyponatremia. Two Avatrombopag-treated patients (0.7%) developed hyponatremia.

Drug Interactions and Special Populations

Moderate or Strong Dual CYP2C9 and CYP3A4 Inducers or Inhibitors: Dose adjustments are recommended for patients with persistent or chronic immune thrombocytopenia. Reduce the starting dosage of Avatrombopag when used concomitantly with a moderate or strong dual inhibitor of CYP2C9 and CYP3A4 (see Table 4 and Table 7) . Moderate or Strong Dual Inducers of CYP2C9 and CYP3A4 Concomitant use with a moderate or strong dual inducer of CYP2C9 and CYP3A4 decreases avatrombopag AUC , which may reduce Avatrombopag efficacy. Increase the recommended starting dosage of Avatrombopag when used concomitantly with a moderate or strong dual inducer of CYP2C9 and CYP3A4 (see Table 4 and Table 7) . Patients with Chronic Liver Disease No dosage adjustments are required for patients with chronic liver disease.

Storage and Purchase Notes

Store according to the package or pharmacist instructions and keep out of reach of children. Before ordering, confirm product name, strength, quantity, price, shipping details, and payment method. After receipt, check packaging, batch number, expiration date, and storage conditions.

Sources

Sources: Doptelet Sprinkle public prescribing information; openFDA/DailyMed public label data. These sources are used for public medical reference. Product information follows this AISTIKA product page.

DisclaimerThis page is for product information and public-label reference only. It does not provide diagnosis, prescription, or individualized medical advice. Consult a physician for treatment decisions.